
Curi Bio: Accelerating next-gen medicine discovery through human cells, systems, and data integration.
Curi Bio was founded with the mission to accelerate the discovery of next-generation medicines by integrating human cells, systems, and data. The company focuses on providing advanced 3D tissue models of disease, biosystems for clinically relevant functional analyses, and AI/ML-enabled insights to inform R&D decision-making. Their integrated platform aims to enhance drug safety, efficacy, and potency assessments, catering primarily to the pharmaceutical and biotechnology sectors.
Notable affiliates and investors in Curi Bio include prominent figures and organizations within the biotech industry, although specific names are not provided. Key achievements include the development of their innovative 3D tissue models and biosystems that have significantly impacted drug discovery processes. Overall, Curi Bio's contributions are pivotal in advancing precision medicine by offering more accurate and human-relevant data for therapeutic development.

Curie.Bio
curie.bio

CuriMeta
curimeta.com

Nano Cures
nanocures.com

CuraSen Therapeutics
curasen.com

DeepCure
deepcure.ai

Insitro
insitro.com

Manifold Bio
manifold.bio

OneThree Biotech
onethree.bio

Culmination Bio
culmination.com

Cellaria
cellariabio.com

Aureka Biotechnologies
aurekabio.com

Cairn Biosciences
cairnbio.com

BioAI Health
bioaihealth.com

Viscient Bio

CuraFi
curafi.com
Companies similar to Curi Bio include Curie.Bio, CuriMeta, Nano Cures and CuraSen Therapeutics.
Curi Bio was founded in 2015.
Curi Bio's headquarters is located in Seattle, WA, US.
Curi Bio's most recent funding round was for $4.4M (USD) in August 2023.
As of Aug 23, 2023, Curi Bio has raised a total of $20.4M (USD).
Curi Bio has 45 employees as of Feb 4, 2024.